Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
03/2012
03/29/2012CA2811023A1 Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines
03/29/2012CA2808556A1 Therapeutic vaccination against active tuberculosis
03/28/2012EP2434022A2 Use of A33 antigens and JAM-IT
03/28/2012EP2434013A1 Promoter for introducing gene into lymphocyte or blood cell and application thereof
03/28/2012EP2433967A2 Humanised antibodies with anti-tumour activity
03/28/2012EP2433966A1 FGFR4 antibodies
03/28/2012EP2433964A1 Peptide inducing xage-1b-specific immune reaction and utilization of same
03/28/2012EP2433650A2 Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
03/28/2012EP2433649A2 Treatment of multiple sclerosis (MS) with campath-1H
03/28/2012EP2433648A2 Vaccine comprising an oil in water emulsion adjuvant
03/28/2012EP2433647A2 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
03/28/2012EP2433646A1 Vaccine against Ehrlichia canis and associated methods
03/28/2012EP2433645A1 Novel malaria vaccine
03/28/2012EP2433644A1 Breast cancer therapeutics
03/28/2012EP2433643A1 Medicaments comprising triptan and botulinum toxin for use in treating headache
03/28/2012EP2433639A2 Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy
03/28/2012EP2432893A1 Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs
03/28/2012EP2432504A1 Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
03/28/2012EP2432503A1 Universal influenza vaccine based on recombinant modified vaccinia ankara virus (mva)
03/28/2012EP2432502A2 Stable, spray dried, immunogenic, viral compositions
03/28/2012EP2432501A2 Secretion-related bacterial proteins for nlrc4 stimulation
03/28/2012EP2432500A2 Engineered type iv pilin of clostridium difficile
03/28/2012EP2432499A2 Modulation of pilr receptors to treat microbial infections
03/28/2012EP2432498A1 A method for keeping an immunogenic composition available for administration to an animal
03/28/2012EP2432476A1 Methods for treating or preventing ophthalmological diseases
03/28/2012EP2432467A1 Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders
03/28/2012EP2066349B1 Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
03/28/2012EP2048954B1 An isolated dna fragment of the sparc human promoter and its use
03/28/2012EP2046807B1 Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
03/28/2012EP2021033B1 Il-1-alpha for use in a method of treatment of atherosclerotic plaques.
03/28/2012EP1846450B1 Antibodies that bind to epha2 and methods of use thereof
03/28/2012EP1651667B1 Protein with fusogenic activity, nucleic acid sequences encoding said protein and pharmaceutical compositions comprising the same
03/28/2012EP1517700B1 Mucin fusion polypeptide vaccines, compositions and methods of use thereof
03/28/2012EP1478395B1 Rapid lateral flow assay for determining exposure to mycobacterium tuberculosis and other mycobacteria
03/28/2012EP1283851B1 Use of il-4r antibodies and compositions thereof
03/28/2012EP1283716B1 Vaccine comprising a tick cement protein
03/28/2012EP1181318B2 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
03/28/2012EP1098909B1 Hybrid human/rodent igg antibody to cd3, and methods of its construction
03/28/2012CN1635901B Remodeling and glycoconjugation of peptides
03/28/2012CN102395604A Humanised antibodies with anti-tumour activity
03/28/2012CN102395603A Diagnosis and treatment of cancer using anti-lgr7 antibody
03/28/2012CN102395602A B-lymphocyte targeting agents for use in a method for the treatment of a disease
03/28/2012CN102395600A Inactivated dengue virus vaccine with aluminium-free adjuvant
03/28/2012CN102392049A Preparation method for hepatitis E virus antigen and product thereof
03/28/2012CN102392048A Recombinant vaccinia virus rMVA-mep for expressing Japanese encephalitis virus E protein multi-epitope antigen and application thereof
03/28/2012CN102392031A Schistosoma japonicum thioredoxin glutathione reductase gene and DNA (deoxyribonucleic acid) vaccine thereof
03/28/2012CN102391992A Monoclonal antibody for resisting human NSCLC and application of monoclonal antibody
03/28/2012CN102391372A Target of liver cancer drug therapy and application of the target
03/28/2012CN102391358A 抗体纯化 Antibody Purification
03/28/2012CN102389575A Genetic engineering oral DNA vaccine and preparation method and application
03/28/2012CN102389574A Application of ITPKA (inositol-trisphosphate 3-kinase A) gene and expression protein thereof in preparing and screening anti-cancer medicament
03/28/2012CN102389570A Antiseptic-free vaccine
03/28/2012CN102389568A Vaccine for preventing golden pompano ulcer
03/28/2012CN102389394A Oil-emulsion vaccine for poultry and preparation method thereof
03/28/2012CN101683524B Method for preparing bacterial ghost by combination of antibacterial peptide and ultrahigh pressure and application thereof
03/28/2012CN101612389B Antiviral drug combination for livestock
03/28/2012CN101374545B Elimination of heterogeneous or mixed cell population in tumors
03/28/2012CN101337070B Freeze-dried attenuated live vaccine for hepatitis A and its preparing process
03/28/2012CN101184499B Intranasal administration of active agents to the central nervous system
03/27/2012US8143387 Engineered antibody-stress protein fusions
03/27/2012US8143386 Fusion proteins of mycobacterium tuberculosis antigens and their uses
03/27/2012US8143385 Nucleic acids coding for antibodies against human IL-21 receptor and uses therefor
03/27/2012US8143379 Human monoclonal antibodies to CTLA-4
03/27/2012US8143218 Treatment of skin, and wound repair, with thymosin beta 4
03/27/2012US8143058 Human CDR-grafted antibody and antibody fragment thereof
03/27/2012US8143054 Fusion protein of HIV regulatory/accessory proteins
03/27/2012US8143024 Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
03/27/2012US8142798 Augmentation of titer for vaccination in animals
03/27/2012US8142797 Therapeutic TB vaccine
03/27/2012US8142796 Monoparamunity inducers based on attenuated rabbit myxomaviruses
03/27/2012US8142795 Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses
03/27/2012US8142794 Hepatitis C virus vaccine
03/27/2012US8142793 Norovirus and Sapovirus antigens
03/27/2012US8142790 Methods of using molecular conjugates comprising monoclonal antibodies to dendritic cells
03/27/2012US8142789 Method for selecting and producing vaccine components and vaccines based thereon
03/27/2012US8142788 PRRSV GP5 based compositions and methods
03/27/2012US8142787 Recombinant chimeric antigens for diagnosis and prevention of scrub typhus
03/27/2012US8142785 Branched beta -(3)-glucan for use as tool in stimulation of immune system of fish
03/27/2012US8142784 Antibody-drug conjugates and methods
03/27/2012US8142783 Methods of treating an inflammatory condition involving VAP-1-mediated adhesion with VAP-1-specific antibodies
03/27/2012US8142782 EGFR inhibitors promote axon regeneration
03/27/2012US8142781 Fusion proteins for blood-brain barrier delivery
03/27/2012US8142780 Anti-bacterial antibodies
03/27/2012US8142779 Treatment of follicular lymphomas using inhibitors of the LT pathway
03/27/2012US8142778 Methods of treatment using CTLA-4 antibodies
03/27/2012US8142777 Monoclonal antibody specific to colon stimulating factor for use in treatment and prevention of rheumatoid arthritis
03/27/2012US8142776 For subcutaneous administration; hypertonic; useful for preventing self-association of reconstituted lyophilized formulations
03/27/2012US8142773 Isolating progenitor cell tissue via antibody specific binding, transfering into recipient host, monitor cell propagation; tissue engineering; regenerative medicine
03/27/2012US8142772 Attack of tumor cells with missing, low or aberrant MHC expression by combining non MHC-restricted T-cells/NK-cells and MHC-restricted cells
03/27/2012US8142760 Vaccination for Lawsonia intracellularis
03/27/2012CA2584482C Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
03/27/2012CA2528007C Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
03/27/2012CA2501818C Pharmaceutical compositions directed to erb-b1 receptors
03/27/2012CA2433792C Enterohemorragic escherichia coli vaccine
03/27/2012CA2378497C Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
03/27/2012CA2309903C Nucleic acid sequences encoding capsaicin receptor
03/27/2012CA2230029C Multi-subtype fiv vaccines
03/23/2012CA2752980A1 Non-aqueous synthesis of polysaccharide-protein conjugates for vaccines
03/22/2012WO2012037546A2 A broadly protective protein of brucella and its use in brucellosis vaccine preparation
03/22/2012WO2012037534A1 Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
1 ... 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 ... 1823